Sartorius and NVIDIA to Develop AI Models for Stem Cell-Derived Organoids, Reducing Animal Testing in Drug Discovery

Sartorius, a leader in life sciences and bioprocessing, is expanding its collaboration with NVIDIA to enhance the development of innovative …

Continue ›››

Nabla Bio Advances Generative Protein Design with $26M Series A Funding

Nabla Bio, a biotechnology firm specializing in generative protein design, has successfully closed a $26 million Series A financing round, …

Continue ›››

Recursion Unveils BioHive-2, Fastest Pharma-Owned Supercomputer

Recursion Pharmaceuticals has achieved a significant milestone by completing BioHive-2, reportedly the fastest supercomputer to be wholly owned and operated …

Continue ›››

Troubling Safety Data Overshadows Efficacy in MacroGenics' Phase 2 Study

MacroGenics, a biotechnology company, has reported concerning safety outcomes in its phase 2 trial of vobramitamab duocarmazine, a B7-H3-directed antibody-drug …

Continue ›››

4 Biotech Startups Developing Breakthrough Drug Modalities

In the dynamic world of drug discovery, companies must continually innovate beyond their existing drug portfolios and modalities. Relying solely …

Continue ›››

DeepMind Launches Advanced AlphaFold Model to Enhance Drug Discovery

Google DeepMind has introduced the latest version of its AlphaFold artificial intelligence model, which aims to assist scientists in designing …

Continue ›››

The Growing Impact of AI in Healthcare

The advent of artificial intelligence (AI) in healthcare has catalyzed an epoch of change, reshaping diagnostic procedures, therapeutic strategies, and …

Continue ›››

Cytomos to Unveil Celledonia™ Technology at London Biotechnology Show 2024

Cytomos, a TechBio company, is gearing up to introduce attendees at the London Biotechnology Show 2024 to its latest development, …

Continue ›››

Is AI impacting the Life Sciences real estate market?

Artificial intelligence (AI) is one of the most disruptive technologies the Life Sciences sector has ever seen. It’s having a …

Continue ›››

Insilico Medicine Relocates Headquarters to Cambridge, Massachusetts

Insilico Medicine, a clinical-stage company specializing in AI-driven drug discovery, has shifted its corporate headquarters from New York to Boston. …

Continue ›››

From Diagnosis to Treatment: The Impact of AI on Rare Disease Drug Development

Drug development for rare (also referred to as orphan) diseases is notoriously challenging. Legislative initiatives, such as the 1983 US …

Continue ›››

Optimising Drug Discovery R&D with Graphs

Data in Life Sciences expert Dr Alexander Jarasch on a new wave of advanced data handling techniques that point the …

Continue ›››